Written by the Nuvirox Research Team
Key points
- There is no published clinical trial testing NAD+ precursors specifically in adult ADHD.
- The closest available data — NR trials in older adults with mild cognitive impairment — found no overall cognitive benefit, and one trial found attention scores trended worse (not better) on NR before statistical adjustment.
- Adult ADHD has well-established, evidence-based treatments that this research doesn't come close to matching.
Short answer: no, at least not as tested so far — and the closest relevant trial data actually cuts against the idea, not for it. This is a case where being direct about a "no" is more useful than a vague maybe.
Why would someone connect NAD+ to ADHD or focus?
Attention, working memory, and executive function are energy-intensive brain processes, and mitochondrial dysfunction has been proposed as one contributing factor in ADHD research more broadly, alongside dopamine and norepinephrine signaling differences that are the primary established biology of the condition. Because NAD+ precursors are marketed heavily around "cognitive energy" and general brain function, it's a natural (if untested) leap for people to wonder whether they'd help with attention or focus specifically.
What does the evidence actually show?
No trial has tested nicotinamide riboside, NMN, or any other NAD+ precursor specifically in adults with ADHD. The closest available human cognitive trials are in older adults with subjective cognitive decline or mild cognitive impairment (MCI) — a different population with a different underlying condition. In one such crossover trial (1 g/day NR for 8 weeks), there was no significant difference in overall cognitive scores between NR and placebo. Notably, on the specific attention subdomain of the cognitive test used, the placebo group actually scored higher than the NR group (a difference that became non-significant after adjusting for age, education, and cognitive status) — the opposite direction you'd want to see if you were hoping NR sharpens attention.
Study snapshot: Closest available trial: NR in older adults with SCD/MCI
| Population | Older adults with subjective cognitive decline or mild cognitive impairment (not ADHD) |
| Design | Crossover, double-blind, randomized, placebo-controlled |
| Dose/duration | 1 g/day NR, 8 weeks |
| Attention finding | Placebo group scored higher on attention subdomain than NR group (became non-significant after adjustment) |
| Overall cognition | No significant difference from placebo |
The honest counterweight
We want to say this plainly rather than hedge: the evidence available doesn't support an NAD+ precursor for ADHD or focus in adults, and the one relevant data point on attention specifically trended in the wrong direction (even though it didn't reach statistical significance after adjustment, in a study not even designed to test ADHD). ADHD is a well-characterized neurodevelopmental condition with a distinct evidence base built around dopaminergic and noradrenergic mechanisms — stimulant and non-stimulant medications, and behavioral therapy, all of which have gone through the kind of rigorous, condition-specific trials that NAD+ precursor research for ADHD simply hasn't undergone.
When to see a doctor
If you suspect you have ADHD as an adult, or existing treatment isn't working well, that's a conversation for a psychiatrist, neurologist, or other clinician experienced in adult ADHD diagnosis and treatment — it's a distinct diagnostic process from general 'brain fog' or fatigue, and effective treatment depends on getting that diagnosis right.
What's actually proven to help adult ADHD
Stimulant medications (methylphenidate- and amphetamine-based) have the strongest, most extensive trial evidence for adult ADHD. Non-stimulant medications (atomoxetine, viloxazine, certain alpha-2 agonists) are effective evidence-based alternatives. Cognitive behavioral therapy adapted specifically for adult ADHD, along with structured environmental and organizational strategies, adds meaningful benefit alongside medication for many people.
How does this fit with other NAD+ and cognition research?
The cognitive research landscape for NAD+ precursors is actually fairly developed in other populations, just not in ADHD specifically — our coverage of whether NAD+ is a nootropic covers the broader brain-function research, and our page on NAD+ and anxiety covers a 2025 randomized trial in a different mental-health-adjacent condition, giving a useful sense of how NAD+ cognitive research tends to be structured and reported when it is done well.
It's also worth being clear about what "focus" and "attention" mean in a research context versus everyday conversation. The clinical trials referenced above use standardized neuropsychological test batteries (like RBANS) with specific attention subdomains, which measure something more precise and different from the everyday experience of feeling distracted or unfocused, discussed in our related coverage of mental fatigue versus physical fatigue. If everyday focus and mental fatigue (rather than a suspected ADHD diagnosis) is your actual concern, that's a different and more general question than what's covered in this article, and sleep, stress, and workload are usually the more productive places to start looking.
It's worth being explicit about one more thing: even the RBANS attention-score difference favoring placebo over NR in the MCI/SCD trial was not the study's primary focus, and became statistically non-significant after adjusting for age, education, and cognitive status. We're not presenting that as strong evidence NR harms attention — only as a reason to be skeptical of any claim that it helps, given that the one relevant data point doesn't support that claim either.
If everyday distractibility, procrastination, or difficulty concentrating is your actual day-to-day concern rather than a suspected clinical ADHD diagnosis, it's worth considering more foundational factors first — sleep quality and duration, caffeine timing, workload and task-switching frequency, and stress levels all have much stronger, more direct evidence for affecting attention and focus than any supplement discussed in this article.
It's also worth noting that ADHD itself is increasingly recognized as commonly persisting into and being newly diagnosed in adulthood, and that adult ADHD symptoms can sometimes overlap with or be mistaken for anxiety, depression, or simple burnout — another reason a proper clinical evaluation matters more here than trying to self-diagnose or self-treat based on general "brain fog" content.
Frequently asked questions
Do NAD+ supplements improve focus or attention?
There's no ADHD-specific trial evidence. The closest relevant human cognitive trial found no overall benefit and a nonsignificant trend toward worse attention scores on NR versus placebo.
Is there any legitimate link between NAD+ biology and ADHD?
Mitochondrial dysfunction has been proposed as a contributing factor in some ADHD research broadly, but this hasn't translated into any NAD+ precursor trial specifically in ADHD populations.
What should I do if I think I have adult ADHD?
Seek evaluation from a clinician experienced with adult ADHD; effective, well-evidenced medication and behavioral treatments exist and shouldn't be replaced with a supplement approach.
From Nuvirox
Why we formulated NAD+ Restore
To be direct: NAD+ Restore is a general wellness supplement, not a treatment for this condition, and it shouldn't be used as a substitute for medical care. If you're separately interested in cellular energy support once your care team is in the loop, here's what's in it.
- 500 mg Nicotinamide Riboside Chloride (NR) — one of the two most-researched NAD+ precursors, within the dose range used in published human trials
- 150 mg trans-resveratrol (Japanese Knotweed) + 50 mg quercetin (Sophora japonica) — polyphenols studied alongside NAD+ pathways for cellular health support
- 10 mg galactomannans from fenugreek — to support absorption
- 60-day money-back guarantee — long enough to actually evaluate it the way the research says you should
The bottom line: current evidence doesn't support NAD+ precursors for adult ADHD or general focus, and the one relevant trial signal actually points the other way. If attention and focus are a real concern, a proper ADHD evaluation and evidence-based treatment will get you much further than a supplement.
References
- Wu L, et al. Cognitive and Alzheimer's disease biomarker effects of oral nicotinamide riboside (NR) supplementation in older adults with subjective cognitive decline and mild cognitive impairment. Alzheimers Dement (Transl Res Clin Interv). 2025;11:e70023. PMID: 39817194.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.